https://www.selleckchem.com/products/iwp-4.html
SVR was achieved in 100 patients (97.1%) at week 12 after treatment. No dangerous or life-threatening adverse events were recorded. Retreatment of HCV genotype 4 patients with quadruple therapy is a good therapeutic option and achieves high response rates with minimal side effects. Retreatment of HCV genotype 4 patients with quadruple therapy is a good therapeutic option and achieves high response rates with minimal side effects. The prognosis of patients with hepatocellular carcinoma (HCC) is poor, with 60% to 70% of patients developing
Aimer
Commentaire
Partagez
